Develops small-molecule medicines that activate gut bitter-taste receptors to address hunger-related conditions, including Prader-Willi syndrome and other metabolic diseases.
10-K for FY2025, filed Mar 23, 2026We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic…View ↗
TAS2Rs are a family of 26 different nutrient-sensing G protein-coupled receptors (GPCRs) that are broadly expressed among vertebrates.…View ↗
Our lead product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for the…View ↗
8-K, filed Nov 13, 2026
In October 2026, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the Company’s Investigational New Drug (IND)…View ↗
Competes with Soleno Therapeutics, Rhythm Pharmaceuticals, Relmada Therapeutics, and Bright Minds Biosciences
10-K for FY2025, filed Mar 23, 2026With respect to ARD-101, VYKAT XR from Soleno Therapeutics is the only FDA-approved treatment for hyperphagia in patients with PWS. We are…View ↗
Loading...